Pregabalin (All indications)

ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15251
R62715
Dudukina (Controls exposed to LTG) (Mixed indications), 2023 Hyperkinetic disorders including Attention deficit hyperactivity disorder (ADHD) 3 months (or more) before pregnancy or during pregnancy population based cohort retrospective exposed to other treatment, sick excluded Adjustment: Yes 1.08 [0.78;1.47]
excluded (control group)
-/-   -/- - -
ref
S15252
R62736
Dudukina (Controls unexposed, NOS) (Mixed indications), 2023 Hyperkinetic disorders including Attention deficit hyperactivity disorder (ADHD) 3 months (or more) before pregnancy or during pregnancy excluded population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.41 [1.11;1.80]
excluded (exposition period)
-/-   -/- - -
ref
Total 0 studies NaN [NaN;NaN] 0 0
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

Sensitivity analysis